Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) is projected to issue its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to announce earnings of ($0.2396) per share and revenue of $33.87 million for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Friday, November 6, 2026 at 9:30 AM ET.
Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.05). Monte Rosa Therapeutics had a negative return on equity of 43.31% and a negative net margin of 560.85%. The business had revenue of $8.97 million during the quarter, compared to the consensus estimate of $12.91 million. On average, analysts expect Monte Rosa Therapeutics to post ($1.23) EPS for the current fiscal year and ($1.56) EPS for the next fiscal year.
Monte Rosa Therapeutics Stock Performance
GLUE stock opened at $10.85 on Thursday. Monte Rosa Therapeutics has a fifty-two week low of $9.68 and a fifty-two week high of $25.77. The stock’s 50 day simple moving average is $12.25 and its 200 day simple moving average is $17.56. The company has a market cap of $925.65 million, a P/E ratio of -6.16 and a beta of 1.37.
Analyst Upgrades and Downgrades
View Our Latest Report on Monte Rosa Therapeutics
Monte Rosa Therapeutics Company Profile
Monte Rosa Therapeutics, Inc is a clinical-stage biotechnology company focused on developing molecular glue degraders, a class of medicines designed to eliminate disease-causing proteins by directing them to the cell’s natural protein-degradation machinery. The company’s approach is intended to address targets that may be difficult to inhibit with conventional small-molecule drugs.
Monte Rosa uses its QuEEN platform to discover and optimize molecular glue degraders for diseases involving dysregulated immune responses and other biological pathways.
Read More
- Five stocks we like better than Monte Rosa Therapeutics
- Boeing Got Its MAX 10 Approval, But Q3 Delivered a Reality Check
- The Invisible AI Backbone: Corning’s AI Fiber Play
- Heavy Metal: Why Nucor Could Be an Overlooked AI Infrastructure Winner
- Why Tesla’s Upside Is About More Than a SpaceX Merger
Receive News & Ratings for Monte Rosa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monte Rosa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
